EP Patent

EP2024745A2 — Assays for diagnosing and evaluating treatment options for fabry disease

Assigned to Amicus Therapeutics Inc · Expires 2009-02-18 · 17y expired

What this patent protects

Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

USPTO Abstract

Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

Patent Metadata

Patent number: EP2024745A2
Jurisdiction: EP
Classification: —
Expires: 2009-02-18
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.